Biotechnology in Thoughts from the Centre

Five strategies that could help biopharma firms get more ROI bang for their R&D buck

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Pharma

This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on the findings from our 2018 Measuring the return from pharmaceutical innovation 2018 report, and what strategies pharma can use to improve their return on investment from R&D.

Continue reading

Posted on 01/02/2019 | 0 Comments

The future awakens: how have our life sciences predictions fared in 2018

By Karen Taylor, Director, Centre for Health Solutions

Blog

Last week we provided an update on the three health care predictions from our November 2017 report - The future awakens: Life Sciences and health care predictions 2022. As promised, this week’s blog reviews developments during 2018 on the three predictions that are more life sciences focused and what we might expect to see in 2019.

Continue reading

Posted on 25/01/2019 | 0 Comments

Patient access to innovative medicine in Europe: A collaborative and value-based approach

By Elizabeth Hampson, Director, Monitor Deloitte and Amen Sanghera, Centre for Health Solutions

Market

This week, we launched our report Patient access to innovative medicine in Europe: A collaborative and value-based approach, which examines the challenges European payers and the pharma industry are facing in funding and bringing the latest innovations to market. Moreover, the report also looks at how key industry stakeholders can work in innovative ways to ensure patients have access to the latest medical innovations.

Continue reading

Posted on 11/01/2019 | 0 Comments

Unlocking R&D productivity - the state of pharmaceutical innovation in 2018

By Matthew Thaxter, Centre for Health Solutions

Pharma

This week, we published our ninth annual report on Measuring the return from pharmaceutical innovation. Our report tracks the projected return on investment that the 12 leading biopharma companies (by 2009 R&D spend) might expect to achieve from their late-stage pipelines. For the fourth consecutive year, we also track the performance of an extension cohort of four more specialised biopharma companies. This week’s blog summarises the key findings from the 2018 report.

Continue reading

Posted on 20/12/2018 | 0 Comments

Launching innovative biopharmaceutical products in China: how to succeed in the fast-moving market?

By Li Xiaofeng, Manager, Monitor Deloitte, London and David Xie, Director, Monitor Deloitte, Shanghai

Chinese-lamp

China has rapidly become one of the larges biopharmaceuticals (biopharma) and medical products markets in the world and is projected to reach $145-175 billion in sales by 2022 (representing a compound annual growth rate of more than 5.5 percent from 2017).1 Profound changes, particularly in relation to shortening the time taken to obtain regulatory approval and widening market access, are making China a more attractive market for biopharma companies to launch innovative medical products. Indeed, since 2017, China has approved record numbers of innovative foreign drugs.2,3 These approvals follow a series of policy moves to provide public funding to enable China’s 1.4 billion population to access new, lifesaving drugs, especially cancer therapies. However many drug makers have had to slash prices so that government will cover the costs of some of the advanced treatments.4

Continue reading

Posted on 14/12/2018 | 0 Comments

My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK

By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care

Regulatory

Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.

Continue reading

Posted on 30/11/2018 | 0 Comments

A bold future for life sciences regulation: Predictions 2025

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.

Continue reading

Posted on 08/11/2018 | 0 Comments

Emerging technologies can boost performance in clinical trials

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Athletes

This week’s blog by Greg Reh, Deloitte’s Global Life Sciences Leader first featured on the US Center for Health Solutions blog, A view from the Center.i In it Greg explores how emerging technologies can improve enrolment in, remove barriers of participation and increase drug adherence in pharma clinical trials.

Continue reading

Posted on 01/06/2018 | 0 Comments

Parts made to order: The future of tissue engineering is here and now

by Dr. Mark Steedman, Research Manager, Centre for Health Solutions

Health-globe

Our recent report The future awakens: Life sciences and health care predictions 2022, uses evidence from today to predict what the world will look like in the year 2022. One of our predictions, ‘The future of medicine is here and now,’ explores how exponential advances in life-extending and precision therapies will improve patient outcomes. Much of the evidence informing this prediction is derived from advances in areas such as genomics, precision medicine and new cancer treatments, including CAR-T cell therapies. However, advances in other scientific areas, such as tissue engineering, are also gaining traction. This week’s blog explores developments in tissue engineering as a whole and zeros in on an exciting new development in retinal tissue engineering.

Continue reading

Posted on 11/05/2018 | 0 Comments

How healthy is pharmaceutical research and development (R&D)?

Pharma R&D

In December 2015 we launched our sixth annual report on ‘Measuring the return from pharmaceutical innovation’.  Our research highlights the difficulties that the largest pharmaceutical companies face in delivering sustainable returns on their late stage R&D pipelines. Indeed, while the cost to develop an asset has increased by a third since we started our analysis six years ago, forecast average peak sales has declined by half. Additionally, our measure of forecast R&D return on investment (RoI) has also shown a significant downward trend, with the average across the 12 companies declining from over ten per cent in 2010 to just over four per cent in 2015.

Continue reading

Posted on 11/03/2016 | 11 Comments